Home › Funds › Lion Point Capital, LP › RPRX
Lion Point Capital, LP position in RPRX
ROYALTY PHARMA PLC · Health Care
Lion Point Capital, LP reported holding 21,400 shares of RPRX (ROYALTY PHARMA PLC) in its Q2 2026 13F filing — a position valued at US$1.2M, representing 5.74% of its reported portfolio and ranking #5 among its reported holdings. Lion Point Capital, LP has disclosed RPRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Lion Point Capital, LP's RPRX position evolved
Lion Point Capital, LP first disclosed a stake in RPRX in Q3 2025 at 21,400 shares (US$755K). The position peaked in Q2 2026 at 21,400 shares, worth US$1.2M. Across 4 filings, Lion Point Capital, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 21,400 shares valued at US$1.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 21.40K | $754.99K | New |
| Q4 2025 | 21.40K | $826.90K | Hold |
| Q1 2026 | 21.40K | $1.03M | Hold |
| Q2 2026 | 21.40K | $1.20M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RPRX and 13F data
RPRX (ROYALTY PHARMA PLC) is a Health Care company. 50 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$601.4M), Baillie Gifford & Co (US$561.6M), Caledonia (Private) Investments Pty Ltd (US$323.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RPRX
- Swedbank AB 10.73M sh · $601.44M · Q2 2026
- Baillie Gifford & Co 10.02M sh · $561.57M · Q2 2026
- Caledonia (Private) Investments Pty Ltd 5.78M sh · $323.85M · Q2 2026
- ROYAL LONDON ASSET MANAGEMENT LTD 4.32M sh · $242.20M · Q2 2026
- Patient Capital Management, LLC 3.60M sh · $201.79M · Q2 2026
- Dorsey Asset Management, LLC 2.46M sh · $137.74M · Q2 2026
- Regal Partners Ltd 2.45M sh · $137.25M · Q2 2026
- NEW SOUTH CAPITAL MANAGEMENT INC 2.39M sh · $133.78M · Q2 2026
- Clark Capital Management Group, Inc. 1.66M sh · $93.24M · Q2 2026
- HOMESTEAD ADVISERS CORP 1.66M sh · $92.92M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.38M sh · $77.67M · Q2 2026
More on Lion Point Capital, LP
FAQ
How long has Lion Point Capital, LP held RPRX?
Lion Point Capital, LP has disclosed RPRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Lion Point Capital, LP's current position in RPRX?
As of Q2 2026, Lion Point Capital, LP holds 21.40K shares of RPRX (ROYALTY PHARMA PLC), valued at $1.20M, representing 5.74% of its reported portfolio and ranking #5.
Has Lion Point Capital, LP been buying or selling RPRX?
In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in RPRX. The position peaked in Q2 2026 at 21.40K shares.
Which other funds hold RPRX?
Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, Caledonia (Private) Investments Pty Ltd, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.